Fighting Cancer: Epigenetic Targets for Oncology
February 23, 2017
Session 2 of the 2017 Drug Design and Delivery Symposium
Epigenetics refers to heritable changes characteristics that can be influences by the environment, but which do not result from changes in the genetic code. Epigenetics is an area of intense current interest in medicinal chemistry, biology, and medicine. Professor Stuart Conway will introduce current understanding of the molecular basis of epigenetic processes, and explain how these findings are being exploited in medicinal chemistry to develop medicines with innovative new mechanisms of action.
What You Will Learn
- A general discussion the molecular components of epigenetics, the epigenetic code hypothesis, and the role of DNA and histone modifications.
- An overview of epigenetic drug classes, including HDACs, methyltransferase inhibitors, demthylase inhibitors, and bromodomain ligands.
- Update on the clinical progress of epigenetic drugs, with a particular focus on newer drug targets, especially “readers”.
The Fine Print
ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.
Experts
Stuart Conway
University of Oxford
Sharan K. Bagal
AstraZeneca
Co-Produced By
;void(0);){kind=link}